Retreatment with venetoclax and rituximab in CLL patients achieved 100% response rates and prolonged progression-free ...

Among patients with MCL still on study in January 2025, 35.3% reported improved MCL-related symptoms, while 5.9% reported ...

Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

After adjustment for other factors, a CFS of 3 or higher and relapsed/refractory disease were the only independent predictors of early zanubrutinib discontinuation.

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...

Please provide your email address to receive an email when new articles are posted on . In this video, Joshua Brody, MD, discusses results from an ongoing phase 1a study of bexobrutideg, a novel ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Single-agent epcoritamab (Epkinly) achieved ...

A new survey from AbbVie digs into the emotional experience of a chronic lymphocytic leukemia (CLL) diagnosis and, according to the company, is the first to break down the results by race/ethnicity to ...

Teddy bears facilitate emotional expression in patients, acting as conduits for revealing true feelings and aiding communication with healthcare providers. Encouraging patients to embrace silence can ...